Stage migration as well as marked variation in stage distribution confounds the direct comparison of survival rates associated with varying degrees of lymphadenectomy for gastric cancer. Data from prospective randomized trials document increased mortality and morbidity associated with D-2 lymphadenectomy. Evidence for improved survival with D-2 lymphadenectomy comes from retrospective and prospective nonrandomized studies that have yet to be validated by any prospective randomized trial. Although it is of value for accurate staging, D-2 lymphadenectomy has yet to be proven therapeutically superior to D-1 resection.
|Original language||English (US)|
|Number of pages||16|
|Journal||Surgical Oncology Clinics of North America|
|State||Published - 1996|
ASJC Scopus subject areas